Anixa Biosciences (ANIX) AI Stock Analysis

• Market Cap: $81.46M
• Dividend Yield: N/A
• Average Volume (3M): 70.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: -100.00%
• EPS Growth: -24.28%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 32,196,860
• 10 Day Avg. Volume: 78,375
• 30 Day Avg. Volume: 70,696
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 484.49
• Price to Cash Flow (P/CF): -8.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $8.50
• Price Target Upside: 241.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Anixa Biosciences faces significant financial challenges, primarily due to its inability to generate revenue and persistent losses, which are compounded by negative cash flows. While its technical indicators show some positive momentum, the negative P/E ratio and lack of dividends make valuation unattractive. The company's financial performance is the primary concern, overshadowing technical and valuation aspects.

Positive Factors

Clinical Trials

An amendment to the protocol for the ongoing Phase 1 trial of its CAR-T therapy in ovarian cancer allows patients who may benefit from a second dose of the CAR-T therapy to receive it and expands enrollment eligibility.

Financial Stability

With $17.3M in cash and a low burn rate, Anixa should have runway into FY27 and through key events generated by its partnerships to unlock investor value.

Partnerships and Collaborations

Anixa's strategic partnerships with leading cancer centers like Cleveland Clinic and Moffitt Cancer Center both validate its programs and ensures efficient capital use while the programs work toward generating clinical proof of concept which should pave the way to later-stage studies.

Negative Factors

Financial Performance

For fiscal 1Q25 ending on January 31, 2025, net loss was $3.2M, or ($0.10) per share.

Market and Commercial Risks

Risks include failure to achieve commercial success due to market size, penetration rate, or competition, and potential dilution risk.

Regulatory and Approval Risks

Risks include failure of cancer vaccine and/or CAR-T therapy in clinical trials and failure to secure regulatory approval.

Anixa Biosciences Business Overview & Revenue Model

Company Description

Anixa Biosciences, Inc. is a biotechnology company focused on leveraging the body's immune system to develop treatments for cancer and infectious diseases. The company operates in the healthcare sector, specifically within the fields of immuno-oncology and infectious diseases. Its core offerings include the development of cancer immunotherapies and vaccines, aiming to innovate in the areas of cancer diagnostics and therapeutics.

How the Company Makes Money

Anixa Biosciences generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These strategic partnerships often involve joint development efforts and shared access to proprietary technologies or compounds. Additionally, Anixa may receive milestone payments and royalties based on the successful development and commercialization of products that utilize its technologies. The company's revenue can also be supplemented by government or private research grants aimed at advancing its scientific endeavors. However, as a company focused on research and development, significant revenue generation is typically reliant on the successful advancement and commercialization of its projects.

Anixa Biosciences Financial Statement Overview

Summary

Anixa Biosciences is facing considerable financial challenges. The lack of revenue and persistent losses are significant issues, compounded by negative cash flows. While the balance sheet shows low leverage and a strong equity position, the company's inability to generate positive income and cash flows presents substantial risk going forward. Improvements in operational efficiency and revenue generation are crucial for future financial health.

Income Statement

Anixa Biosciences has faced significant challenges in generating revenue, with a complete drop to zero in the most recent year. The company has consistently experienced negative EBIT and net income, indicating ongoing operational and profitability issues. The lack of revenue growth and persistent losses highlight the company's struggles in achieving financial stability.

Balance Sheet

The company's balance sheet shows a relatively strong equity position compared to its liabilities, with a low debt-to-equity ratio, indicating low financial leverage. However, the continued negative net income affects the return on equity, which remains poor. The high equity ratio suggests financial stability, but the lack of profitability is a concern.

Cash Flow

Anixa Biosciences demonstrates negative operating and free cash flows, which is a concern for liquidity and sustainability. The company has managed to secure financing to cover its cash outflows, but the inability to generate positive cash flows from operations remains a significant weakness.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	210.00K	2.47B	512.50K	0.00
	Gross Profit
-15.00K	0.00	49.00K	2.47B	127.50K	-90.16K
	EBIT
-13.61M	-13.83M	-11.01M	-13.88M	-13.14M	-9.98M
	EBITDA
-13.60M	-13.83M	-10.96M	-13.73M	-13.08M	-10.00M
	Net Income Common Stockholders
-12.48M	-12.55M	-9.81M	-13.49M	-12.95M	-10.13M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
978.96K	19.92M	23.84M	29.69M	35.73M	9.06M
	Total Assets
8.26M	21.59M	25.52M	30.41M	36.26M	9.45M
	Total Debt
5.00M	232.00K	175.00K	221.00K	259.48K	55.20K
	Net Debt
4.02M	-1.04M	-740.00K	-12.14M	-28.87M	-6.36M
	Total Liabilities
5.58M	2.70M	2.15M	2.21M	1.49M	1.19M
	Stockholders Equity
2.68M	20.00M	24.34M	29.05M	35.44M	8.76M
Cash Flow		Free Cash Flow
-7.93M	-7.33M	-6.21M	-6.49M	-4.94M	-6.19M
	Operating Cash Flow
-7.93M	-7.33M	-6.21M	-6.49M	-4.94M	-6.18M
	Investing Cash Flow
6.85M	4.28M	-5.60M	-10.73M	-3.92M	-305.79K
	Financing Cash Flow
1.14M	3.42M	366.00K	452.00K	31.57M	9.41M

Anixa Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.49
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANIX, the sentiment is Negative. The current price of 2.49 is below the 20-day moving average (MA) of 2.91, below the 50-day MA of 2.95, and below the 200-day MA of 2.99, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 38.43 is Neutral, neither overbought nor oversold. The STOCH value of 15.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANIX.

Anixa Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANIX	49 Neutral	$81.46M	―	-58.80%	―	-100.00%	-24.28%
Sector *	48 Neutral	$6.35B	1.19	-46.87%	2.63%	17.16%	1.34%
VSTM	47 Neutral	$265.67M	―	-526.33%	―	―	14.39%
IBIO	46 Neutral	$31.85M	―	-123.28%	―	650.00%	89.72%
AIM	35 Underperform	$6.86M	―	-388.69%	―	-15.84%	47.31%
CYCC	28 Underperform	$44.37M	―	-807.39%	―	-89.76%	80.28%

Anixa Biosciences Corporate Events

Anixa Biosciences Reports Promising Phase 1 Vaccine Results

Anixa Biosciences, in collaboration with Cleveland Clinic, unveiled promising results from their Phase 1 trial of a breast cancer vaccine aimed at triple-negative breast cancer (TNBC). The vaccine, based on groundbreaking research, showed safety and efficacy in activating immune responses in patients. As they gear up for a Phase 2 study in 2025, the vaccine’s potential to become a preventive measure against aggressive breast cancer offers hope for future treatments and partnerships with major pharmaceutical firms.